Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 2/20 | 0.38 |
| ▸ | P2RY12 | Q9H244 | 3/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 5/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 5/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22910813 | 0.92 | PDK2 (0.36) | MGLLP2RY12NPC1ALOX15PDK2 | |
| SCHEMBL22911086 | 0.91 | CNR2 (0.36) | MGLL | |
| SCHEMBL22911093 | 0.91 | MGLL (0.43) | MGLLP2RY12HIF1AHCRTR1HCRTR2 | |
| SCHEMBL16759905 | 0.91 | MGLL (0.43) | MGLLP2RY12HIF1AHCRTR1HCRTR2 | |
| SCHEMBL22911087 | 0.91 | ENPP2 (0.36) | MGLLKMT2ANAMPT | |
| SCHEMBL22911144 | 0.90 | MGLL (0.37) | MGLLHIF1AHCRTR1HCRTR2NPC1 | |
| SCHEMBL22910574 | 0.90 | MGLL (0.32) | MGLLP2RY12ALOX15MAPT | |
| SCHEMBL22911089 | 0.89 | HCRTR1 (0.34) | MGLLHIF1AHCRTR1HCRTR2NPC1 | |
| SCHEMBL22910578 | 0.88 | ALDH1A1 (0.37) | MGLLHCRTR1HCRTR2PDK2 | |
| SCHEMBL16961755 | 0.87 | HCRTR1 (0.43) | MGLLP2RY12HIF1AHCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210015792-A1 | OCTAHYDRO-CYCLOBUTA[1,2-c;3,4-c']DIPYRROL-2-YL | HOFFMANN-LA ROCHE INC. (US) | 2021-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210015792-A1 | OCTAHYDRO-CYCLOBUTA[1,2-c;3,4-c']DIPYRROL-2-YL | NPY1R, NPY2R, DECR1 | MGLL 3367/4885P2RY12 2685/4885HIF1A 3162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.